Amarantus, Generex to co-develop MANF-based therapeutic
Under the agreement, MANF-based therapeutic will be developed using Generex’s RapidMist technology in conjunction with oral-insulin spray technology Oral-lyn. Amarantus chief scientific officer John Commissiong said MANF’s profile
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.